Lead Product(s): Isoquercitrin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISQ950AN
Highest Development Status: Phase III Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2021
SPA supports protocol for Phase 3 Trial of Isoquercetin to effect thromboembolic events in metastatic pancreatic cancer patients. Isoquercetin employs a novel pathway that is based on a new mechanism of action to prevent or reverse thrombus formation.